EMAS position statement: management of uterine fibroids

Faustino R Pérez-López, Faustino R. Pérez‐López, Lía Ornat, Iuliana Ceauşu, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Ιrene Lambrinoudaki, Karin Schenck-Gustafsson, Karin Schenck‐Gustafsson, Tommaso Simoncini, Florence Trémollières, Florence Tremollieres, Margaret Rees, EMAS
Maturitas · 2014 · vol. 79(1) , pp. 106–116 · doi:10.1016/j.maturitas.2014.06.002 · PMID:24975954 · W1970099367
Guideline OA: closed CC0 ⤵ 11 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This position statement from EMAS outlines current best practices for the diagnosis and medical management of uterine fibroids in women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Uterine fibroids (also termed leiomyomas or myomas) are the most common tumors of the female reproductive tract. AIM: The aim of this position statement is to provide and critically appraise evidence on the management of women with uterine fibroids. METHODS: Literature review and consensus of expert opinion. RESULTS AND CONCLUSIONS: Many uterine fibroids are asymptomatic and require no intervention, although it is advisable to follow up patients to document stability in size and growth. Fibroid-associated symptoms include heavy menstrual bleeding and pain or pelvic discomfort. The association between infertility and fibroids increases with age. Fibroids do not increase the risk of malignant uterine disease and leiomyosarcomas are extremely rare (less than one in 1000). It is unknown at present whether leiomyosarcoma represents de novo growth or malignant transformation from benign uterine fibroids. Treatment options for symptomatic fibroids include pharmacologic, surgical and radiologically guided interventions. The range of medical treatments allows flexible management of fibroid-related symptoms; the options include tranexamic acid, non-steroidal anti-inflammatory drugs, contraceptive steroids, gonadotropin-releasing hormone analogs, antiprogesterone, and selective progesterone receptor modulators. However, these medical options do not remove the tumors and symptoms may return when treatment is stopped. Surgical and radiologically guided procedures may be tailored to age, general health, and individual patient wishes. Hysterectomy is the most effective treatment, although in some cases myomectomy may be sufficient to control symptoms. Alternatives to surgery include uterine artery embolization, myolysis and ablation by high-intensity focused ultrasound (guided with magnetic resonance imaging or ultrasound). The choice of treatment depends on fibroid size, the underlying symptoms and their severity and the woman's desire for subsequent fertility and pregnancy, as well as efficacy and need for repeated interventions.

My notes (saved in your browser only)

MeSH descriptors

Leiomyoma Uterine Neoplasms Antifibrinolytic Agents Antifibrinolytic Agents Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal Decision Making Embolization, Therapeutic Embolization, Therapeutic Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone High-Intensity Focused Ultrasound Ablation High-Intensity Focused Ultrasound Ablation Humans Hysterectomy Hysterectomy Leiomyoma Leiomyoma Patient Care Planning

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (9)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:14:02.509446+00:00
unpaywall
last seen: 2026-10-26T06:31:53.434635+00:00
License: CC0 · commercial use OK